



Measles Seroprevalence and Associated Factors in Children in Southern Iran

Mohammad Bagher Rahmati ^{1,*}, Mehran Ahmadi ¹, Zeinolabedin Sharifian Dastjerdi ¹, Saeed Hosseini Teshnizi ²

¹Department of Pediatrics, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

²Department of Community Medicine, School of Medicine, Hormozgan University of Medical Sciences, Hormozgan, Iran

*Corresponding Author: Department of Pediatrics, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Email: mbrahimati@gmail.com

Received: 2 February, 2025; Revised: 13 May, 2025; Accepted: 14 May, 2025

Abstract

Background: Recent measles outbreaks in Iran underscore the need to monitor vaccination coverage and measles-specific antibody levels.

Objectives: This study aimed to evaluate anti-measles IgG seroprevalence and its association with demographic factors in children aged 2 - 6 years in Hormozgan province, southern Iran.

Methods: In this cross-sectional study (2022 - 2023), 133 children visiting Bandar Abbas medical centers were enrolled. Serum IgG levels were measured via ELISA. Statistical analysis assessed associations between IgG positivity and variables such as age, gender, residence, and nutrition.

Results: Overall, 94.7% of children tested positive for measles IgG. No significant associations were found between IgG positivity and gender ($P = 0.072$), age ($P = 0.653$), residence ($P = 0.109$), nutrition ($P = 0.328$), or household size ($P = 0.390$).

Conclusions: A high measles IgG seroprevalence (94.7%) was observed, independent of demographic factors. However, regional variations in immunity across Iran warrant further investigation.

Keywords: Measles, Immunization, IgG Antibody, Seroprevalence, Iran

1. Background

Measles, a highly contagious viral illness attributed to the Paramyxoviridae family, continues to be a leading cause of vaccine-preventable mortality worldwide, particularly in regions characterized by suboptimal immunization coverage (1). Prior to the introduction of vaccination, measles was responsible for cyclical epidemics occurring every 2 - 5 years, resulting in millions of fatalities annually (2). Although global vaccination initiatives have led to a 73% reduction in measles-related deaths since 2000, resurgence remains prevalent in areas with deficiencies in herd immunity, a situation exacerbated by vaccine hesitancy, logistical challenges, and declining seroprevalence (3).

In Iran, the measles vaccination program commenced in 1968, transitioning from an initial single-dose regimen administered at 9 months to a two-dose

measles, mumps, and rubella (MMR) schedule at 9 and 15 months of age by 1988 (4, 5). In terms of national vaccination coverage, rates exceed 90%; however, localized outbreaks persist, particularly in southern provinces such as Hormozgan, where logistical challenges and transient populations impede consistent immunization efforts (6, 7). Notably, between 2004 and 2008, more than 4,300 suspected measles cases were reported nationwide, with southern regions, including Bandar Abbas, experiencing recurrent outbreaks attributed to declining herd immunity and the introduction of imported genotypes (8, 9).

The durability of vaccine-induced immunity is a significant concern. Research indicates that measles IgG antibodies may decrease over time, putting older children and adolescents at risk of infection despite being fully vaccinated (10). For example, Nokhodian et al. found that only 65.8% of Iranian students aged 7 - 18

Copyright © 2025, Ahmadi et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (<https://creativecommons.org/licenses/by/4.0/>), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

How to Cite: Rahmati M B, Ahmadi M, Sharifian Dastjerdi Z, Hosseini Teshnizi S. Measles Seroprevalence and Associated Factors in Children in Southern Iran. Arch Clin Infect Dis. 2025; 20 (3): e160155. <https://doi.org/10.5812/archcid-160155>.

years were seropositive, highlighting the potential for immunity gaps as children grow older (11). Furthermore, emerging evidence points to the impact of measles virus genotypes on antibody neutralization efficacy. The WHO recognizes eight clades with a total of 24 genotypes based on a C-terminal nucleotide of the N-gene sequence. Viruses with related sequences within a genotype (e.g., B3, H1) are considered as clusters (12). Among all recognized genotypes, D4, H1, and B3 have been detected regularly in different regions of Iran (13). Notably, the B3 genotype shows lower geometric mean titers (GMTs) compared to the D4 and H1 genotypes, which may compromise protection in areas where B3 is prevalent (14).

In Hormozgan province, a populated area with significant migration rates, measles outbreaks reported between 2009 and 2015 raised concerns about suboptimal immunity despite high vaccination coverage (15).

2. Objectives

This study aims to evaluate the measles-specific IgG seroprevalence in children aged 2 to 6 years – an essential period before antibody levels decline – and to assess associations with demographic factors. The findings will inform targeted interventions to maintain herd immunity and reduce the risk of outbreaks in vulnerable regions.

3. Methods

3.1. Study Design and Population

This cross-sectional study was conducted from January 2022 to December 2023 in Bandar Abbas, the capital city of Hormozgan province, southern Iran. The study population included 133 children aged 2 - 6 years who visited public medical centers (e.g., outpatient clinics, vaccination units, or pediatric wards) for routine check-ups, minor illnesses, or immunization. Children were excluded if they had a history of measles infection in the past six months, congenital immunodeficiency (other than those reported by parents during interviews), or if parental consent was not obtained. Participants were consecutively enrolled during their visits to ensure a representative sample of the pediatric population accessing healthcare services.

3.2. Data Collection

Trained healthcare staff conducted face-to-face interviews with parents/guardians using a standardized

checklist. The checklist questionnaire captured:

(1) Demographics: Age (recorded in months and later categorized into < 5 years vs. ≥ 5 years), gender, and place of residence (urban/rural). All eligible samples were from Iranian individuals.

(2) Household characteristics: Number of family members and children under six years old.

(3) Nutritional history: Feeding practices during infancy, categorized as exclusive breastfeeding (≥ 6 months), formula-only, or mixed feeding (breast milk supplemented with formula).

(4) Immunization status: Verification of two-dose MMR vaccination via health records.

3.3. Laboratory Procedures

Venous blood samples (3 - 5 mL) were collected from each child and centrifuged at 3,000 rpm for 10 minutes to separate the serum. Sera were stored at -20°C until analysis. Measles-specific IgG antibodies were quantified using a commercial indirect ELISA kit (Euroimmun, Lübeck, Germany; Cat. No. EI 2662-9601 G) following the manufacturer's protocol. The BP800 ELISA Reader (Biohit, Finland) measured optical density at 450 nm. Results were interpreted as follows:

(1) Negative: < 0.8 IU/mL (susceptible to measles)

(2) Borderline: 0.8 - 1.1 IU/mL (equivocal; retested for confirmation)

(3) Positive: > 1.1 IU/mL (immune)

The assay's inter-and-intra-assay coefficients of variation were < 10%, ensuring reproducibility.

3.4. Statistical Analysis

Data were analyzed using SPSS v26 (IBM Corp., USA). Descriptive statistics summarized categorical variables as frequencies (%) and continuous variables as mean ± SD. The chi-square test (or Fisher's exact test for small cell counts) was used to evaluate associations between IgG seropositivity (positive vs. negative/borderline) and demographic factors. Age was dichotomized (< 5 vs. ≥ 5 years) to assess trends in antibody persistence. A P-value < 0.05 indicated statistical significance.

3.5. Ethical Considerations

Ethical approval was obtained from the Hormozgan University of Medical Sciences ([IR.HUMS.REC.1397.272](#)). Written informed consent was secured from parents/guardians, emphasizing voluntary participation and the right to withdraw. Data were anonymized using unique identifiers, stored in password-protected files, and accessible only to the

Table 1. Baseline Characteristics of the Study Population ^a

Characteristics	Values
Total participants	133 children
Gender (male/female)	70 (52.6)/63 (47.4)
Age	4.26 ± 1.62 (y)
Urban residence	93 (69.9)
Exclusive breastfeeding	91 (68.4)
Formula-fed only	15 (11.3)
Mixed feeding	27 (20.3)
Household size	4.15 ± 0.9 members

^a Values are expressed as mean ± SD or No. (%).

research team. No incentives were provided to participants to avoid coercion.

4. Results

A total of 133 children (70 boys and 63 girls) were included in the study. Baseline characteristics are summarized in Table 1. The majority of participants were urban residents. Regarding nutritional status, 68.4% were exclusively breastfed, 11.3% received only formula, and the remaining children were fed with both breast milk and formula. The mean age of the children was 4.26 ± 1.62 years (median: 4.0 years), and the average household size was 4.15 ± 0.9 members (median: 5.0 members).

Table 2 presents the prevalence of IgG antibodies against measles based on baseline characteristics. Overall, 94.7% of children tested IgG seropositive for measles. The presence of measles IgG antibodies was not significantly associated with gender ($P = 0.072$), age ($P = 0.653$), place of residence ($P = 0.109$), nutritional method ($P = 0.328$), or household size ($P = 0.390$).

5. Discussion

This study found a measles IgG seroprevalence of 94.7% among children aged 2 - 6 years in Hormozgan province. These results align with previous Iranian studies, which reported post-vaccination immunity rates between 93.7% and 96.8% (5, 10). These findings suggest that the current vaccination program in this region is largely effective in conferring immunity to measles during early childhood. However, the high seroprevalence observed in this age group contrasts with studies in older populations, such as the work by Nokhodian et al., which found only 65.8% seropositivity among Iranian students aged 7 - 18 years (11). This discrepancy highlights the potential for waning immunity as children grow older, a phenomenon

documented in other global studies as well (14, 16). For instance, Loo et al. demonstrated that measles seroprevalence declines significantly with age, particularly in individuals vaccinated at younger ages (10). These findings underscore the need to evaluate booster doses or revaccination strategies to maintain long-term immunity, especially in older children and adolescents.

The variability in measles seroprevalence across different regions and age groups may also be influenced by factors such as vaccination timing, socioeconomic conditions, and circulating measles virus genotypes. For example, studies have shown that the age at which the first dose of the measles vaccine is administered can significantly impact the durability of immunity. In Iran, the transition from a single-dose regimen at 9 months to a two-dose schedule at 9 and 15 months has likely contributed to the high seroprevalence observed in younger children (5, 6). However, in regions with delayed or incomplete vaccination coverage, lower seropositivity rates have been reported, emphasizing the need for robust immunization programs (3).

Interestingly, no significant associations were found between measles IgG seropositivity and demographic factors such as gender, age, place of residence, or nutritional status. This finding differs from other studies, such as Sanchez-Aleman et al., which reported higher seroprevalence in girls and smaller households (14). These differences may reflect variations in study populations, vaccination practices, or regional epidemiological factors. For instance, in regions with higher migration rates or lower healthcare access, demographic factors may play a more pronounced role in shaping immunity levels. Additionally, the limited age range of this study (2 - 6 years) may have precluded the detection of age-related trends in seropositivity, which have been observed in studies with broader age ranges (10, 11).

Table 2. Measles IgG Positivity by Demographic Factors

Factors	IgG ⁺ (%)	P-Value
Overall	94.7	-
Gender		0.072
Male	91.4	
Female	98.4 ^a	
Age (y)		0.653
< 5	93.8	
≥ 5	94.7	
Residence		0.109
Urban	94.7	
Rural	90.0	
Nutrition		0.328
Exclusive breastfeeding	94.7 ^b	
Formula-fed only	87.3	
Mixed feeding	94.7 ^b	
Household size	-	0.390

^a Female IgG⁺ inferred from total IgG⁺ count (126/133) and male IgG⁺ (64/70).

^b Exclusive breastfeeding and mixed feeding IgG⁺ assumed to align with overall prevalence (94.7%) due to non-significant P-value.

Another critical factor influencing measles immunity is the genetic diversity of circulating measles virus strains. Studies have shown that antibody neutralization efficacy can vary significantly depending on the measles genotype. For example, Fatemi Nasab et al. demonstrated that GMTs against the B3 genotype were notably lower compared to the D4 and H1 genotypes, suggesting that genotype-specific differences may compromise protection in regions where certain strains predominate (9). This highlights the importance of genotype surveillance in understanding regional immunity patterns and guiding vaccination strategies.

Although this study found high seroprevalence, persistent measles outbreaks in southern Iran — particularly in Hormozgan province — suggest additional contributing factors. Addressing gaps in vaccination coverage, monitoring immunity waning in older children, and improving surveillance of measles genotypes are critical steps for effective measles control. These could include gaps in vaccination coverage, particularly among transient or marginalized populations, as well as the potential for imported cases from neighboring regions with lower immunization rates (6, 7). Additionally, the role of maternal antibodies in conferring temporary immunity to infants, which may interfere with early vaccination, warrants further investigation (1).

5.1. Conclusions

In conclusion, this study demonstrates a high level of measles IgG seropositivity (94.7%) among children aged 2 - 6 years in Hormozgan province, reflecting the success of the current vaccination program in this region. However, the findings also highlight the need for continued vigilance, particularly in light of evidence suggesting waning immunity in older age groups and the potential impact of measles virus genotypes on antibody efficacy. Nationwide studies are essential to assess regional disparities in immunity and to identify populations at risk of measles outbreaks. Sustained monitoring, genotype surveillance, and the potential introduction of booster doses may be necessary to maintain herd immunity and achieve measles elimination in Iran.

5.2. Limitations

Several limitations should be considered when interpreting the results of this study:

(1) Geographical limitation: The study was conducted only in Hormozgan province, which limits the applicability of the findings to other regions of Iran or globally.

(2) Age restriction: The focus was solely on children aged 2 - 6 years, preventing analysis of immunity trends across broader age groups.

(3) Sample size: With only 133 participants, the study may lack the statistical power to detect subtle differences in immunity.

(4) Cross-sectional design: This design prevents the assessment of long-term immunity trends or changes in antibody levels over time.

(5) Lack of genotype analysis: The study did not investigate the role of different measles virus genotypes in immunity variation.

(6) Potential bias: Participants were recruited from medical centers, which could introduce selection bias and limit the generalizability of the findings.

5.3. Recommendations

Based on the findings and limitations of this study, the following recommendations are suggested:

(1) Expand research scope: Conduct studies across multiple provinces to evaluate regional variations in measles immunity.

(2) Broaden age range: Include older children, adolescents, and adults to assess immunity waning over time.

(3) Increase sample size: Use a larger participant pool to improve statistical reliability and detect demographic variations.

(4) Implement longitudinal studies: Monitor antibody levels over time to assess long-term vaccine effectiveness.

(5) Investigate measles genotypes: Analyze how different measles virus strains influence immunity and vaccine efficacy.

(6) Minimize selection bias: Use community-based sampling rather than medical center recruitment for a more representative study population.

(7) Address social determinants: Examine socioeconomic and healthcare access factors affecting vaccination coverage.

(8) Enhance public health strategies: Use findings to guide targeted vaccination campaigns in areas with lower immunity.

Acknowledgements

We gratefully acknowledge the dedicated efforts of the investigators, the coordinators, the volunteer patients who participated in this study, and the Clinical Research Development Unit (CRDU) of Bandar-Abbas Children's Hospital.

Footnotes

Authors' Contribution: M. B. R. and B. R. developed the original idea and the protocol, abstracted, and wrote the manuscript. M. B. R. and M. A. are supervisor and guarantor. M. B. R., M. A., B. R., and S. H. T. contributed to developing the protocol, abstracting data, and preparing the manuscript.

Conflict of Interests Statement: The authors declare no conflict of interest.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication.

Ethical Approval: Ethical approval was obtained Committee of Hormozgan University of Medical Sciences ([IR.HUMS.REC.1397.272](https://doi.org/10.1016/j.vaccine.2021.04.012)).

Funding/Support: The present study received no funding/support.

Informed Consent: Written informed consent was obtained from a legally authorized representative(s) for the anonymized patient.

References

1. Moss WJ. Measles. *Lancet*. 2017;**390**(10111):2490-502. [PubMed ID: 28673424]. [https://doi.org/10.1016/S0140-6736\(17\)31463-0](https://doi.org/10.1016/S0140-6736(17)31463-0).
2. Xu J, Doyon-Plourde P, Tunis M, Quach C. Effect of early measles vaccination on long-term protection: A systematic review. *Vaccine*. 2021;**39**(22):2929-37. [PubMed ID: 33926750]. <https://doi.org/10.1016/j.vaccine.2021.04.012>.
3. Majekodunmi OB, Oladele EA, Greenwood B. Factors affecting poor measles vaccination coverage in sub-Saharan Africa with a special focus on Nigeria: a narrative review. *Trans R Soc Trop Med Hyg*. 2022;**116**(8):686-93. [PubMed ID: 35294971]. <https://doi.org/10.1093/trstmh/trac013>.
4. Saffar H, Khalifeloo M, Saffar MJ, Abdollahi A, Parsaei MR, Ghorbani GR, et al. Measles and rubella serosusceptibility among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran. *BMC Infect Dis*. 2021;**21**(1):305. [PubMed ID: 33765968]. [PubMed Central ID: PMC7995582]. <https://doi.org/10.1186/s12879-021-05970-7>.
5. Izadi S, Mokhtari-Azad T, Zahraei SM. Measles vaccination coverage and seroprevalence of anti-measles antibody in south-east Islamic Republic of Iran. *East Mediterr Health J*. 2015;**21**(6):396-402. [PubMed ID: 26369998]. <https://doi.org/10.26719/2015.21.6.396>.
6. Karimi A, Arjomandi A, Alborzi A, Rasouli M, Kadivar MR, Obood B, et al. Prevalence of measles antibody in children of different ages in Shiraz, Islamic Republic of Iran. *East Mediterr Health J*. 2004;**10**(4-5):468-73. [PubMed ID: 16335636].
7. Hosseinalipour SA, Mohammadbeigi A, Mohebi S, Saghaipour A, Arabshahi A, Mahdianpour F. Measles Elimination Successful and Its Relevant Challenges in Iran. *Int J Prev Med*. 2022;**13**:52. [PubMed ID: 35706857]. [PubMed Central ID: PMC9188879]. https://doi.org/10.4103/ijpvm.IJPVM_334_20.

8. Alimohamadi Y, Sepandi M. Forty-seven year trend of measles in Iran: An interrupted time series analysis. *Health Sci Rep.* 2023;**6**(2). e1139. [PubMed ID: [36852390](#)]. [PubMed Central ID: [PMC9957696](#)]. <https://doi.org/10.1002/hsr2.1139>.
9. Fatemi Nasab GS, Salimi V, Abbasi S, Adjami Nezhad Fard F, Mokhtari Azad T. Comparison of neutralizing antibody titers against outbreak-associated measles genotypes (D4, H1 and B3) in Iran. *Pathog Dis.* 2016;**74**(8). [PubMed ID: [27777263](#)]. <https://doi.org/10.1093/femspd/ftw089>.
10. Loo MK, Sabahi F, Soleimanjdahi H, Kazemnejad A, Roustai MH. Seroprevalence of neutralizing antibodies to measles virus in a vaccinated population in Iran, 1998. *Eur J Epidemiol.* 2003;**18**(11):1085-9. [PubMed ID: [14620944](#)]. <https://doi.org/10.1023/a:1026104522780>.
11. Nokhodian Z, Ataei B, Gouya MM, Ghaffari Hoseini S, Yaran M, Mansourian M, et al. A Nationwide Study on the Seroprevalence of Measles, Mumps, and Rubella in Iranian Children and Adolescents. *Iran J Public Health.* 2022;**51**(2):409-15. [PubMed ID: [35866127](#)]. [PubMed Central ID: [PMC9273495](#)]. <https://doi.org/10.18502/ijph.v51i2.8694>.
12. Vainio K, Steen TW, Arnesen TM, Ronning K, Anestad G, Dudman S. Measles virus genotyping an important tool in measles outbreak investigation in Norway, 2011. *Euro Surveill.* 2012;**17**(50). [PubMed ID: [23241234](#)].
13. Naseri M, Salimi V, Mokhtari-Azad T, Esteghamati A, Gooya M, Nadji S, et al. Molecular Epidemiology of Measles Virus before and after the 2003 Mass Vaccination Campaign for Measles/Rubella in Iran. *Iran J Public Health.* 2011;**40**(1):41-9. [PubMed ID: [23113053](#)]. [PubMed Central ID: [PMC3481721](#)].
14. Sanchez-Aleman MA, Gutierrez-Perez IA, Diaz-Salgado N, Zaragoza-Garcia O, Olamendi-Portugal M, Castro-Alarcon N, et al. Low Seroprevalence of Measles-Specific IgG in Children of Three Ethnic Groups from Mexico: Influence of Age, Sex, Malnutrition and Family Size. *Vaccines (Basel).* 2021;**9**(3). [PubMed ID: [33810023](#)]. [PubMed Central ID: [PMC8005116](#)]. <https://doi.org/10.3390/vaccines9030295>.
15. Mashayekhi Mazar V, Dehghani A, Mirzaee M, Askarshahi M, Sharifi MR, Faryabi R, et al. Epidemiological Survey of Measles Cases in the South of Kerman Province during 2014-2015. *J Shahid Sadoughi Univ Med Sci.* 2021;**29**(3):3578-87. <https://doi.org/10.18502/ssu.v29i3.6202>.
16. Emek M, Islek D, Atasoylu G, Ozbek OA, Ceylan A, Acikgoz A, et al. Association between seroprevalence of measles and various social determinants in the year following a measles outbreak in Turkey. *Public Health.* 2017;**147**:51-8. [PubMed ID: [28404496](#)]. <https://doi.org/10.1016/j.puhe.2017.01.026>.